Debiopharm and Ascenta Therapeutics Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various Tumors
9/7/2011 6:03:26 AM
More...
|
Ascenta Therapeutics Inc. and The Leukemia & Lymphoma Society Announce Agreement to Develop AT-406 for Leukemia
12/6/2010 11:58:07 AM
More...
|
Sanofi-Aventis (France) (SASY.PA), Ascenta Therapeutics Inc. Agree Up To $398 Mln Cancer R&D Deal
6/4/2010 7:48:18 AM
More...
|
Ascenta Therapeutics Inc. Announces Presentation of Results From a Dose-Ranging Study of AT-101 With Standard Therapy in Patients With Glioblastoma Multiforme
10/26/2009 8:48:43 AM
More...
|
Ascenta Therapeutics Inc. Receives Clearance to Initiate Clinical Trials With AT-406
9/10/2009 7:56:53 AM
More...
|
Ascenta Therapeutics Inc. Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 American Society of Clinical Oncology Annual Meeting
6/1/2009 8:48:10 AM
More...
|
Ascenta Therapeutics Inc. Announces Multiple Presentations on AT-101 at 2009 American Society of Clinical Oncology Annual Meeting
5/26/2009 9:01:46 AM
More...
|
Ascenta Therapeutics Inc. Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models
4/21/2009 8:55:27 AM
More...
|
Ascenta Therapeutics Inc. Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
2/27/2009 9:59:57 AM
More...
|
Ascenta Therapeutics Inc. Highlights Multiple Data Presentations at This Week's AACR-NCI-EORTC International Conference in San Francisco
10/24/2007 9:56:26 AM
More...
|
|